Point72 Europe’s Novo Nordisk NVO Stock Holding History

Point72 Europe’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24,698	Closed	-$3.53M	–	161
2024 Q2	$3.53M	Buy	+24,698	New	+$3.27M	0.29%	94

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Europe's NVO Position: Q3 2024 in Review

Point72 Europe sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 24,698 shares — an estimated $3.53M sold.

Point72 Europe first reported a position in NVO in Q2 2024 and held it in 1 quarter. The position peaked at $3.53M in Q2 2024. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

Point72 Europe reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
Point72 Europe sold 24,698 Novo Nordisk shares in Q3 2024, an estimated $3.53M.
Point72 Europe first reported a position in Novo Nordisk in Q2 2024 and held it in 1 quarter.
Point72 Europe's Novo Nordisk position peaked at $3.53M in Q2 2024.
1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Point72 Europe's 13F filing for Q3 2024, filed 14 Nov 2024.